Opthea Completes Enrollment in Wet AMD Phase 3 Trial
Ticker: OPTEY · Form: 6-K · Filed: May 28, 2024 · CIK: 1815620
Sentiment: neutral
Topics: clinical-trial, biotech, drug-development
TL;DR
Opthea just finished enrolling patients in its big Phase 3 trial for wet AMD drug. Big step!
AI Summary
Opthea Limited announced on May 28, 2024, the completion of enrollment in its pivotal Phase 3 clinical program for sozinibercept, a potential treatment for wet age-related macular degeneration (AMD). This milestone signifies progress in their clinical development efforts for the drug.
Why It Matters
This completion is a critical step towards potentially bringing a new treatment option to patients suffering from wet AMD, a leading cause of vision loss.
Risk Assessment
Risk Level: medium — Clinical trial enrollment completion is positive, but the ultimate success and approval of the drug are still uncertain.
Key Players & Entities
- Opthea Limited (company) — Registrant
- sozinibercept (drug) — Investigational drug for wet AMD
- wet age-related macular degeneration (AMD) (disease) — Condition being treated
- May 28, 2024 (date) — Date of announcement
FAQ
What is the significance of completing enrollment in the Phase 3 clinical program?
Completing enrollment is a crucial milestone that indicates the trial is progressing as planned and is on track for further stages, moving the drug closer to potential regulatory review.
What condition is sozinibercept intended to treat?
Sozinibercept is being investigated for the treatment of wet age-related macular degeneration (AMD).
What type of filing is this 6-K report?
This is a Report of Foreign Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
When was this report filed with the SEC?
The report was filed on May 28, 2024.
What exhibit is included with this 6-K filing?
Exhibit 99.1 is included, which is a Press Release titled 'Opthea Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD'.
Filing Stats: 155 words · 1 min read · ~1 pages · Grade level 13.6 · Accepted 2024-05-28 06:05:54
Filing Documents
- opt_opthea_completes_enr.htm (6-K) — 23KB
- opt-ex99_1.htm (EX-99.1) — 33KB
- img260626642_0.jpg (GRAPHIC) — 61KB
- img260626642_1.jpg (GRAPHIC) — 61KB
- 0000950170-24-064873.txt ( ) — 225KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized. OPTHEA LIMITED (Registrant) By: /s/ Frederic Guerard Name: Frederic Guerard Title: Chief Executive Officer Date: 05/28/2024